In animal studies, entecavir suppressed viral load and staved off liver cancer, the Interscience Conference on Antimicrobial Agents and Chemotherapy in Toronto, Canada, was told.
Researchers from developers, Bristol-Myers Squibb, told how they tested the drug on 11 woodchucks infected with the virus. Treatment lasted for 14 months.
Five animals received treatment for another 22 months - a total of three years.
One animal died of liver cancer after nine months but after 14 months nine animals had undetectable viral loads. And of the five animals who discontinued treatment, two showed no evidence of the virus returning for 27 months. Two others died of cancer.
HBV undetectable in animals treated for 3 years.
The virus remained undetectable in the five animals who were treated for a full three years - but one still died of liver cancer.
"Entacavir treatment appeared to extend the life span of treated animals and prevent the onset of liver cancer. These studies support further development of entacavir for the treatment of chronic HBV infections in man," researcher Richard Colonno told the conference.
Report Copyright: Englemed Health News at http://www.internationalmedicalnews.com